- Danaher (NYSE:DHR) has signed an agreement to sell its label-free biomolecular characterization, chromatography hardware and resins, and microcarriers and particle validation standards businesses to Sartorius AG (OTC:SARTF) for ~$750M.
- The agreement was signed as a step towards obtaining regulatory approval for its pending acquisition of the GE Biopharma business.
- The transaction is expected to be closed in Q1 2020.